White Paper: Induced Pluripotent Stem Cell (iPSC) Based Therapies
Enhanced Confidence in Characterization of iPSC-Based Therapeutic Candidates
Current pre-clinical approaches to characterizing iPSC-based therapies may miss significant genomic and transcriptomic heterogeneity. Read our perspective on how emerging single-cell multiomics technologies put more comprehensive data in researchers’ hands.
In this white paper, you'll read about:
- The genomic and transcriptomic heterogeneity in iPSC culture and reprogramming
- Why single-cell multiomic analysis is necessary to characterize and validate iPSC-based therapeutic candidates
- Tools that make it possible to precisely, sensitively detect insertions, deletions, substitutions, larger genomic alterations, alternative splicing events, and altered gene expression across the entire genome – and attribute these variants to individual cells.